Patents by Inventor Mark A. Jensen

Mark A. Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210188975
    Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.
    Type: Application
    Filed: June 28, 2020
    Publication date: June 24, 2021
    Applicant: Iterative Therapeutics, Inc.
    Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
  • Publication number: 20190055310
    Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 21, 2019
    Applicant: Iterative Therapeutics, Inc.
    Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
  • Patent number: 10000819
    Abstract: This invention relates to a rapid method for detection and characterization of Escherichia coli bacteria serotype O157:H7 based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect E. coli O157:H7 in a food or water sample, such as a beef enrichment. The present invention further relates to replication compositions and kits for carrying out the method of the present invention.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: June 19, 2018
    Assignee: Qualicon Diagnostics LLC
    Inventors: Daniel R. Demarco, Mark A. Jensen, Stephen Varkey
  • Patent number: 9528162
    Abstract: This invention relates to a rapid method for detection and characterization of STEC bacteria based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect STEC bacteria in a food or water sample, such as a beef enrichment. The present invention further relates to isolated polynucleotides, replication compositions, kits, and reagent tablets for carrying out the method of the present invention.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: December 27, 2016
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Stephen Varkey, Daniel R. DeMarco, Mark A. Jensen
  • Publication number: 20160201116
    Abstract: This invention relates to a rapid, accurate method for detection and characterization of Salmonella enteritidis and/or Salmonella typhimurium based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect S. enteritidis and/or S. typhimurium in an environmental sample. The present invention further relates to replication compositions and kits for carrying out the method of the present invention.
    Type: Application
    Filed: August 19, 2014
    Publication date: July 14, 2016
    Inventors: Mark A. Jensen, Daniel R. Demarco, Stephen Varkey, Jun Li
  • Publication number: 20160194395
    Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.
    Type: Application
    Filed: August 6, 2015
    Publication date: July 7, 2016
    Applicant: ITERATIVE THERAPEUTICS, INC.
    Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White
  • Publication number: 20150376686
    Abstract: This invention relates to a rapid method for detection and characterization of Escherichia coli bacteria serotype O157:H7 based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect E. coli O157:H7 in a food or water sample, such as a beef enrichment. The present invention further relates to replication compositions and kits for carrying out the method of the present invention.
    Type: Application
    Filed: February 18, 2014
    Publication date: December 31, 2015
    Applicant: E.I. DU PONT DE NEMOURS AND COMPANY
    Inventors: Daniel R. Demarco, Mark A. Jensen, Stephen Varkey
  • Publication number: 20150292039
    Abstract: Disclosed herein are methods for the identification of the species, serotype, and strain of a fungi. Also disclosed are primers for use in detecting such fungi and kits comprising such primers.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 15, 2015
    Inventors: Xuan Peng, Mark A. Jensen
  • Patent number: 9127063
    Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.
    Type: Grant
    Filed: March 10, 2013
    Date of Patent: September 8, 2015
    Assignee: Iterative Therapeutics, Inc.
    Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
  • Patent number: 9040242
    Abstract: Disclosed herein are methods for the identification of the species, serotype, and strain of a microorganism. Also disclosed are primers for use in detecting such microorganisms and kits comprising such primers.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: May 26, 2015
    Assignee: E I DUPONT DE NEMOURS AND COMPANY
    Inventors: Anjana Agarwal, Mark A. Jensen
  • Patent number: 8986698
    Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.
    Type: Grant
    Filed: February 12, 2011
    Date of Patent: March 24, 2015
    Assignee: Iterative Therapeutics, Inc.
    Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
  • Publication number: 20140323710
    Abstract: This invention relates to a rapid method for detection and characterization of STEC bacteria based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect STEC bacteria in a food or water sample, such as a beef enrichment. The present invention further relates to isolated polynucleotides, replication compositions, kits, and reagent tablets for carrying out the method of the present invention.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: Stephen Varkey, Daniel R. DeMarco, Mark A. Jensen
  • Patent number: 8802371
    Abstract: This invention relates to a rapid method for detection and characterization of STEC bacteria based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect STEC bacteria in a food or water sample, such as a beef enrichment. The present invention further relates to isolated polynucleotides, replication compositions, kits, and reagent tablets for carrying out the method of the present invention.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: August 12, 2014
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Stephen Varkey, Daniel R. DeMarco, Mark A. Jensen
  • Publication number: 20130078634
    Abstract: This invention relates to a rapid method for detection and characterization of STEC bacteria based on the presence of nucleic acid sequences, in particular, to a PCR-based method for detection, and to oligonucleotide molecules and reagents and kits useful therefore. This method is preferably employed to detect STEC bacteria in a food or water sample, such as a beef enrichment. The present invention further relates to isolated polynucleotides, replication compositions, kits, and reagent tablets for carrying out the method of the present invention.
    Type: Application
    Filed: September 28, 2012
    Publication date: March 28, 2013
    Inventors: Stephen Varkey, Daniel R. DeMarco, Mark A. Jensen
  • Publication number: 20130029341
    Abstract: Disclosed herein are methods for the identification of the species, serotype, and strain of a microorganism. Also disclosed are primers for use in detecting such microorganisms and kits comprising such primers.
    Type: Application
    Filed: July 19, 2012
    Publication date: January 31, 2013
    Inventors: Anjana AGARWAL, Mark A. Jensen
  • Patent number: 8163289
    Abstract: The present invention concerns inventive polypeptides. The present invention also concerns compositions and vaccines comprising the inventive polypeptides. In other embodiments of the invention, the inventive polypeptides are provided to a subject, used to vaccinate, or used to induce immunity. Other embodiments include methods for making the inventive polypeptides and nucleic acids used to encode the inventive polypeptides.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: April 24, 2012
    Assignee: Iterative Therapeutics, Inc.
    Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
  • Publication number: 20110195067
    Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.
    Type: Application
    Filed: February 12, 2011
    Publication date: August 11, 2011
    Applicant: Iterative Therapeutics, Inc.
    Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
  • Patent number: 7897729
    Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: March 1, 2011
    Assignee: Iterative Therapeutics, Inc.
    Inventors: Barry G. W. Arnason, Mark A. Jensen, David M. White
  • Patent number: 7655774
    Abstract: The present invention is directed to ancestral and COT nucleic acid and amino acid sequences, methods for producing such sequences and uses thereof, including prophylactic and diagnostic uses.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: February 2, 2010
    Assignee: University of Washington
    Inventors: James I. Mullins, Allen G. Rodrigo, Gerald H. Learn, Fusheng Li, David C. Nickle, Mark A. Jensen
  • Publication number: 20090117133
    Abstract: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc?R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc?R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the framework region of human IgG1. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of Fc?R in autoimmune disorders.
    Type: Application
    Filed: September 18, 2008
    Publication date: May 7, 2009
    Applicant: ITERATIVE THERAPEUTICS, INC.
    Inventors: Barry G.W. Arnason, Mark A. Jensen, David M. White